@article{812d9a863d94460dbcbca0a67232b4aa,
title = "Tissue is still the issue for precision oncology: A novel web-based platform for lesion selection and biopsy specimen acquisition",
keywords = "Biopsy, Cancer, Precision oncology, Tissue",
author = "Vivek Subbiah",
note = "Funding Information: Conflicts of interest: Vivek Subbiah reports unrelated research grants from LOXO Oncology/Eli Lilly, Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune; an advisory board/consultant position with LOXO Oncology/ Eli Lilly, Relay Therapeutics, Blueprint medicines, Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, and Medimmune; travel funds from Pharmamar, Incyte, ASCO, and ESMO; other support from Medscape; all outside the submitted work. Funding Information: Sources of Support: Vivek Subbiah is supported by National Institutes of Health grant R01CA242845; MD Anderson is supported by Cancer Center Support Grant (P30 CA016672).",
year = "2021",
month = nov,
doi = "10.36401/JIPO-21-X5",
language = "English (US)",
volume = "4",
pages = "176--177",
journal = "Journal of Immunotherapy and Precision Oncology",
issn = "2666-2345",
publisher = "Innovative Healthcare Institute",
number = "4",
}